SCHEMBL19658591

SCHEMBL19658591

CC(=O)N(C)C1CCN(c2ncc(C)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.44
MAP4K4 O95819 1/20 0.42
SYK P43405 1/20 0.41
VNN1 O95497 3/20 0.40
HDAC6 Q9UBN7 1/20 0.39
KCNH2 Q12809 1/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP2C19 P33261 1/20 0.39
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
AOC3 Q16853 3/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MCHR1 Q99705 1/20 0.37
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
CYP11B2 P19099 1/20 0.36
ACACB O00763 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19658660 0.87 RIPK1 (0.44) MAP4K4SYKVNN1CCNCCDK8
SCHEMBL26151349 0.85 KDM4E (0.55) GPR119MAP4K4KDM4ECYP2C19SMN1; SMN2
SCHEMBL30731299 0.85 ACACB (0.43) GPR119MAP4K4VNN1KDM4EPOLB
SCHEMBL19652119 0.85 AAK1 (0.42) GPR119VNN1HDAC6KCNH2KDM4E
SCHEMBL19658459 0.83 JAK2 (0.42) MAP4K4SYK
SCHEMBL16003398 0.81 KCNH2 (0.47) GPR119MAP4K4HDAC6KCNH2
SCHEMBL20152894 0.78 KDM4E (0.50) GPR119HDAC6KCNH2KDM4ECYP2C19
SCHEMBL19658457 0.78 KDM4E (0.54) KDM4EPOLBSMN1; SMN2USP2HPGD
SCHEMBL17753772 0.78 GPR119 (0.45) GPR119HDAC6KCNH2KDM4ECYP2C19
SCHEMBL19658493 0.76 MCHR1 (0.49) GPR119SYKKDM4ECYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 GPR119 988/4885MAP4K4 1182/4885SYK 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.